Properdin deposition has been recognized in glomeruli of patients with acute and chronic nephritis and lupus nephritis, and low serum properdin levels have been found in these disorders. These findings suggest that properdin may be involved in the production of glomerular damage and that low properdin levels may be due to hypercatabolism. The study was designed to examine the metabolism of properdin in normal subjects and to look for an abnormality in five patients with systemic lupus erythematosus with renal involvement and in six patients with membranoproliferative glomerulonephritis or dense deposit disease (MPGN). Highly purified human properdin was prepared by elution from zymosan, followed by DEAE-cellulose and carboxymethyl-Sephadex chromatography, and labeled with 125I by the iodine monochloride method. Parameters of metabolism were determined by monitoring plasma and urinary radioactivity at frequent intervals after the intravenous injection of 1-2 muCi of labeled material. The fractional catabolic rate (FCR) of properdin in normal subjects was found to have a very narrow range of 0.78-1.0,% of the plasma pool per hour (mean 0.95%). In systemic lupus erythematosus, the FCR was regularly elevated with a range of 1.21-2.30% (mean 1.70%). In MPGN, FCR was elevated in three patients (1.22, 1.94, and 2.08%) and within or below the normal range in three (0.78, 1.00, and 1.00%). Properdin levels were reduced in two patients who had the highest FCR's noted in the study. Properdin synthetic rates in normals varied from 4.1 to 14.3 mug/kg per h (mean 9.1) and was not found to be reduced in any patient. Properdin catabolism was found to be normal in a patient deficient in the C3b inactivator. These studies show that properdin is hypercatabolized in patients with renal disease and that decreased properdin levels when they occur in these patients can be entirely explained on the basis of this hypercatabolism.
J B Ziegler, F S Rosen, C A Alper, W Grupe, I H Lepow
Title and authors | Publication | Year |
---|---|---|
Mathematical Modelling of Alternative Pathway of Complement System
S Bakshi, F Cunningham, EM Nichols, M Biedzka-Sarek, J Neisen, S Petit-Frere, C Bessant, L Bansal, LA Peletier, S Zamuner, PH van der Graaf |
Bulletin of Mathematical Biology | 2020 |
Clinical and functional consequences of anti‐properdin autoantibodies in patients with lupus nephritis
M Radanova, G Mihaylova, D Ivanova, M Daugan, V Lazarov, L Roumenina, V Vasilev |
Clinical & Experimental Immunology | 2020 |
Role of properdin in complement-mediated kidney diseases
MF van Essen, JM Ruben, AP de Vries, C van Kooten |
Nephrology Dialysis Transplantation | 2018 |
Properdin: a tightly regulated critical inflammatory modulator
AZ Blatt, S Pathan, VP Ferreira |
Immunological Reviews | 2016 |
Properdin and factor h: opposing players on the alternative complement pathway "see-saw"
L Kouser, M Abdul-Aziz, A Nayak, CM Stover, RB Sim, U Kishore |
Frontiers in immunology | 2013 |
INHERITED DEFICIENCIES OF COMPLEMENT PROTEINS : with special reference to congenital deficiency of the regulatory protein factor I
JE RASMUSSEN |
APMIS | 1991 |
INHERITED DEFICIENCIES OF COMPLEMENT PROTEINS: with special reference to congenital deficiency of the regulatory protein factor I
JE RASMUSSEN |
APMIS | 1991 |
Advances in Human Genetics
H Harris, K Hirschhorn |
1990 | |
Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum
JT Mayes, RD Schreiber, NR Cooper |
Journal of Clinical Investigation | 1984 |
Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus
D Adu, DG Williams |
Clinical & Experimental Immunology | 1984 |
Pathophysiology of Plasma Protein Metabolism
G Mariani |
1984 | |
Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema
M Quastel, R Harrison, M Cicardi, CA Alper, FS Rosen |
Journal of Clinical Investigation | 1983 |
Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus
MR Daha, HM Hazevoet, J Hermans, LA van Es, A Cats |
Clinical & Experimental Immunology | 1983 |
Molecular aspects of complement activation
K Whaley, A Ferguson |
Molecular Aspects of Medicine | 1981 |
Immunological Aspects of Rheumatology
WC Dick |
1981 | |
Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins
MT Aguado, LH Perrin, R Ramirez, PA Miescher, PH Lambert |
Clinical & Experimental Immunology | 1980 |
Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus
K Whaley, PH Schur, S Ruddy |
Clinical & Experimental Immunology | 1979 |
Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis
K Whaley, D Ward, S Ruddy |
Clinical & Experimental Immunology | 1979 |
Severe systemic lupus erythematosus with nephritis in a boy with deficiency of the fourth component of complement
JG Schaller, BG Gilliland, HD Ochs, JP Leddy, LC Agodoa, SI Rosenfeld |
Arthritis & Rheumatism | 1977 |
Pathways of complement activation in chronic discoid lupus
MA Schrager, NF Rothfield |
Arthritis & Rheumatism | 1977 |
Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus
MA Schrager, NF Rothfield |
Journal of Clinical Investigation | 1976 |
C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase
K Whaley, PH Schur, S Ruddy |
Journal of Clinical Investigation | 1976 |
Activation of the alternative complement pathway in systemic lupus erythematosus
MR Wilson, CM Arroyave, RM Nakamura, JH Vaughan, EM Tan |
Clinical & Experimental Immunology | 1976 |